1.. Introduction
================

Human leukocyte antigen-G (HLA-G), a non-classical major histocompatibility complex class I (MHC-I) antigen, has well-recognized tolerogenic properties ([@b1-ol-0-0-7407]). HLA-G has been detected under physiological conditions in fetal tissues, adult immune-privileged organs and cells of the hematopoietic lineage ([@b1-ol-0-0-7407]), as well as under pathological conditions in cancer, viral infections, inflammatory diseases, autoimmune diseases and transplantation ([@b2-ol-0-0-7407]).

HLA-G was first detected at the maternal-fetal interface in the trophoblast, possibly performing a role in the modulation of the maternal immune system during pregnancy ([@b3-ol-0-0-7407]). The expression of HLA-G in fetal tissue successfully suppressed the local immune response in the placenta, therefore inducing maternal-fetal tolerance, preventing the fetus from being recognized as a non-self tissue and protecting it from lysis mediated by natural killer (NK) cells ([@b4-ol-0-0-7407]). Similarly, HLA-G expression in tumors can also protect cancer cells from NK cell and cytotoxic T lymphocyte (CTL)-mediated destruction ([@b5-ol-0-0-7407]). In this context, HLA-G expression may be a mechanism used by cancer cells to escape host immune surveillance.

Differing from classical HLA, the HLA-G gene presents limited coding region variability ([@b6-ol-0-0-7407]). Variation at the 5′ upstream regulatory region (5′URR) and 3′ untranslated region (3′UTR) has been observed most frequently ([@b6-ol-0-0-7407]). Several lines of evidence have indicated that HLA-G polymorphisms affect the expression level of HLA-G, the production of different isoforms and the pattern of alternative splicing ([@b7-ol-0-0-7407],[@b8-ol-0-0-7407]). Polymorphisms in HLA-G have been studied in pathophysiological conditions, revealing that HLA-G polymorphisms are associated with numerous types of disorders, including pre-eclampsia ([@b9-ol-0-0-7407]), recurrent spontaneous abortion ([@b10-ol-0-0-7407]), asthma ([@b11-ol-0-0-7407]), systemic lupus erythematosus ([@b12-ol-0-0-7407]) and pemphigus vulgaris ([@b13-ol-0-0-7407]). In addition, several isolated segments of the HLA-G gene have been studied in different tumor types and were identified to be associated with tumor progression ([@b14-ol-0-0-7407]).

The present review discusses HLA-G expression and its gene polymorphisms in tumors, and analyzes its underlying mechanisms in promoting tumor development. Furthermore, the possible clinical applications of HLA-G (or sHLA-G) as a diagnostic and prognostic biomarker for cancer, and as a potential therapeutic target for cancer biotherapy are considered.

2.. Structure and physiology of HLA-G
=====================================

HLA-G is a MHC-I antigen encoded by a gene on chromosome 6 at region 6p21.3 ([@b15-ol-0-0-7407]). It has been termed as a non-classical HLA class I molecule, since it differs from classical HLA class I molecules due to its unique promoter region, limited polymorphism, restricted tissue distribution and immunosuppressive function ([@b16-ol-0-0-7407]). The structure of HLA-G is different to HLA class I ([@b17-ol-0-0-7407]). The main difference resides in the presence of a stop codon in exon 6, which generates a shorter HLA-G protein compared with the classical HLA-G class I molecule ([@b17-ol-0-0-7407]). Compared with the high incidence of polymorphism in classical HLA class I molecules, HLA-G exhibits limited genetic polymorphism with only 50 alleles, which are distributed within the α1, α2 and α3 domains ([@b15-ol-0-0-7407]). HLA-G consists of seven isoforms, including four membrane-bound isoforms (HLA-G1-HLA-G4) and three secreted isoforms (sHLA-G; HLA-G5-HLA-G7), which are generated by alternate splicing of primary transcripts ([@b18-ol-0-0-7407]). sHLA-Gs contain an intron 4-encoded stop codon, resulting in the lack of transmembrane domain ([@b19-ol-0-0-7407]). Membrane-bound HLA-G1 and its soluble counterpart, HLA-G5 have been most studied in tissues or cells of organisms ([@b1-ol-0-0-7407]). In addition, sHLA-G molecules may also be shed via the proteolytic cleavage of membrane-bound HLA-G1 ([@b20-ol-0-0-7407]). Therefore, sHLA-G consists of sHLA-G1 and HLA-G5, of which HLA-G5 is the primary component ([@b20-ol-0-0-7407]). HLA-G1 and HLA-G5 are composed of heavy chains consisting of three globular domains (α1, α2, α3), which non-covalently bind to β2-microglobulin (β2-m), and a nonapeptide, while the other isoforms lacking one or two globular domains can bind neither β2-m nor present peptides ([@b21-ol-0-0-7407]).

In healthy individuals, HLA-G was first detected in extra-villous cytotrophoblast at the maternal-fetal interface, being regarded as a molecule that modulates the maternal immune system during pregnancy ([@b3-ol-0-0-7407]). It is also expressed by amnion epithelial cells, endothelial cells of fetal blood vessels in the placenta, erythroblasts, macrophages, antigen-presenting cells and dendritic cells (DCs), as well as by immune-privileged organs of adults, including the thymus, cornea and pancreatic islets ([@b22-ol-0-0-7407]). Additionally, ectopic HLA-G expression can be induced in various pathological conditions, including cancer, viral infections, inflammatory diseases, viral infections, autoimmune diseases and transplantation ([@b1-ol-0-0-7407]).

Considered as immunomodulatory molecules, HLA-G antigens can induce immunological tolerance by inhibiting certain immune-competent cells ([@b22-ol-0-0-7407]). The immune-suppressive function of HLA-G antigens may be mediated by binding membrane-bound and sHLA-G to their specific inhibitory receptors ([@b23-ol-0-0-7407]). Regarding these receptors, HLA-G antigens preferentially act as ligands for immunoglobulin-like transcript 2 (ILT2) and immunoglobulin-like transcript 4 (ILT4) ([@b23-ol-0-0-7407]). ILT2 is expressed by B cells/T cells/NK cells/monocytes/DCs, and ILT4 is presented on monocytes/macrophages/DCs ([@b24-ol-0-0-7407],[@b25-ol-0-0-7407]). In addition, HLA-G antigens were also reported to be ligands for the killer cell immunoglobulin-like receptor \[KIR2DL4/p49 (CD158d)\], which is expressed on NK cells ([@b26-ol-0-0-7407]). The direct interactions between HLA-G proteins and their specific inhibitory receptors promote the maintenance of tolerance at different stages of the immune response, consisting of differentiation, proliferation, cytolysis and cytokine secretion ([@b27-ol-0-0-7407]). It was also demonstrated that HLA-G could modulate the differentiation of DCs by interacting with ILT4, which requires the interleukin (IL)-6-signal transducer and activator of transcription 3 (STAT3) signaling pathway and results in the recruitment of Src homology region 2 domain-containing phosphatase (SHP)-1 and SHP-2 protein tyrosine phosphatases ([@b28-ol-0-0-7407]). Furthermore, the cell cycle of human-activated T cells can be suppressed by activating SHP-2 phosphatase and inhibiting the mechanistic target of rapamycin pathway mediated by HLA-G ([@b29-ol-0-0-7407]). Notably, HLA-G may upregulate the inhibitory receptors in immune cells, which may precede an immune response and be involved in immune escape mechanisms by increasing their activation thresholds ([@b30-ol-0-0-7407]).

In addition to these direct effects, HLA-G can implement its indirect immune-inhibitory function through the expression of non-classical HLA class I molecule HLA-E ([@b16-ol-0-0-7407],[@b31-ol-0-0-7407]). HLA-E can directly bind the peptides derived from HLA-G, and the HLA-E/peptide complexes can interact with the inhibitory receptor CD94/NKG2A, which is predominantly expressed on NK cells ([@b31-ol-0-0-7407]). Thus, the effect of HLA-E on immune cells is of great importance for the inhibition of NK and T cell reactivity ([@b31-ol-0-0-7407]). Indeed, HLA-G-mediated immune tolerance may be extended to induce regulatory T cells (T~regs~), a subpopulation of T cells possessing abilities to modulate the immune system, abrogate the autoimmune reaction and maintain the tolerance-to-self antigens ([@b32-ol-0-0-7407]). For instance, in the presence of HLA-G, CD4^+^ and CD8^+^ T cells may lose their capability to respond to antigenic stimulation and be differentiated into T~regs~ ([@b32-ol-0-0-7407]).

3.. HLA-G expression and plasma sHLA-G levels in cancer and their association with clinical parameters
======================================================================================================

Since the ectopic expression of HLA-G in tumor cells was first described in melanoma by Paul *et al* ([@b5-ol-0-0-7407]) in 1998, a high frequency of HLA-G expression and plasma sHLA-G levels have been observed successively in different solid tumor types, as well as in hematological malignancies, including melanoma ([@b33-ol-0-0-7407],[@b34-ol-0-0-7407]), breast cancer ([@b35-ol-0-0-7407]--[@b44-ol-0-0-7407]), lung cancer ([@b45-ol-0-0-7407]--[@b49-ol-0-0-7407]), hepatocellular carcinoma ([@b50-ol-0-0-7407]--[@b53-ol-0-0-7407]), colorectal cancer ([@b49-ol-0-0-7407],[@b54-ol-0-0-7407]--[@b58-ol-0-0-7407]), gastric cancer ([@b49-ol-0-0-7407],[@b59-ol-0-0-7407]--[@b61-ol-0-0-7407]), esophageal carcinoma ([@b49-ol-0-0-7407],[@b62-ol-0-0-7407]--[@b65-ol-0-0-7407]), nasopharyngeal carcinoma ([@b66-ol-0-0-7407]), laryngeal lesions ([@b67-ol-0-0-7407]), bladder transitional cell carcinoma ([@b68-ol-0-0-7407]), renal cell carcinoma ([@b69-ol-0-0-7407]--[@b72-ol-0-0-7407]), cervical cancer ([@b73-ol-0-0-7407]), thyroid carcinoma ([@b74-ol-0-0-7407],[@b75-ol-0-0-7407]), neuroblastoma ([@b76-ol-0-0-7407],[@b77-ol-0-0-7407]), glioblastoma ([@b78-ol-0-0-7407]--[@b81-ol-0-0-7407]) and myeloid leukemia ([@b82-ol-0-0-7407]). HLA-G expression in various cancer types is listed in [Table I](#tI-ol-0-0-7407){ref-type="table"}, and data regarding plasma sHLA-G levels detected by ELISA are presented in [Table II](#tII-ol-0-0-7407){ref-type="table"}. As shown in [Table II](#tII-ol-0-0-7407){ref-type="table"}, in the majority of cancer types, serum sHLA-G levels were significantly higher in patients with cancer compared with in the healthy controls. Notably, sHLA-G levels were similar between patients with bladder transitional cell carcinoma (TCC) and healthy controls ([@b68-ol-0-0-7407]).

However, the associations between increased HLA-G expression and the clinical parameters of patients with cancer remain conflicting. Although there was a significant association between increased HLA-G expression levels and certain clinical parameters, including advanced disease stage, poor histological grade, higher tumor grade, presence of metastasis, shorter survival time, greater tumor size, tumor recurrence or tumor invasion in many types of tumors ([@b27-ol-0-0-7407]), the association was not detected in other tumors, including bladder TCC ([@b68-ol-0-0-7407]) and acute myeloid leukemia ([@b82-ol-0-0-7407]). Although several studies have demonstrated that high serum sHLA-G levels were associated with aggressive behavior in cancer, histological type, tumor-node-metastasis stage or a shorter survival time of patients suffering from breast cancer, papillary thyroid carcinoma (PTC) and lung cancer among others, no clear associations were identified between the plasma sHLA-G levels and the clinicopathological parameters in colorectal cancer, hepatocellular carcinoma, esophageal carcinoma, renal cell carcinoma and gastric cancer ([@b38-ol-0-0-7407],[@b43-ol-0-0-7407],[@b45-ol-0-0-7407],[@b83-ol-0-0-7407]). Notably, numerous factors may affect sHLA-G expression ([@b65-ol-0-0-7407],[@b82-ol-0-0-7407]). The upregulated plasma IL-10 level in primary esophageal squamous cell carcinoma was determined to be associated with high sHLA-G levels ([@b65-ol-0-0-7407]). In addition, sHLA-G levels have been established as associated with the deficiency of anterior myelodysplasia along with higher leukocytosis in acute myeloid leukemia ([@b82-ol-0-0-7407]). Notably, contradictions exist in the same type of tumor between different studies. For instance, Kren *et al* ([@b70-ol-0-0-7407]) confirmed that HLA-G is upregulated in renal cell carcinoma tissues and that it is associated with a worse prognosis. By contrast, Reimers *et al* ([@b84-ol-0-0-7407]) reported that weak HLA-G expression was associated with a poor prognosis and a significantly worse survival. These contradictions may possibly be attributed to differing ethnicities in the patient cohorts, varied criteria of patient selection, the methods used and factitious surgical errors.

4.. HLA-G polymorphisms promote cancer development
==================================================

Compared with classical HLA, the HLA-G gene presents limited coding region variability ([@b6-ol-0-0-7407]). However, variations at the 5′URR and at the 3′UTR have been observed in numerous previous studies ([@b6-ol-0-0-7407],[@b85-ol-0-0-7407]--[@b87-ol-0-0-7407]). Recently, a number of studies indicated that HLA-G polymorphisms are associated with HLA-G expression ([@b41-ol-0-0-7407]), cancer susceptibility ([@b88-ol-0-0-7407]--[@b91-ol-0-0-7407]) and cancer development ([@b86-ol-0-0-7407]).

Although it remains a controversial issue as to where HLA-G transcription begins, the polymorphisms at the 5′URR and haplotypes at the 3′UTR are considered to affect HLA-G expression ([@b7-ol-0-0-7407]). In healthy Brazilian and French individuals, the 14-bp del/del genotype exhibited higher sHLA-G levels compared with the 14-bp ins/ins genotype ([@b85-ol-0-0-7407]). Additionally, in patients with invasive ductal carcinoma, 14-bp ins/del polymorphisms may induce a higher expression of the HLA-G molecule compared with 14-bp ins/ins and 14-bp del/del polymorphisms ([@b41-ol-0-0-7407]). The differential expression levels were attributed to the fact that polymorphic sites at the 5′URR coincided with the known transcription factor binding sites, and that the polymorphic sites at 3′UTR affect mRNA stability and the binding of specific microRNAs ([@b85-ol-0-0-7407]).

It has previously been demonstrated that 14-bp polymorphisms may be a genetic risk factor for susceptibility to several types of cancer ([@b87-ol-0-0-7407],[@b88-ol-0-0-7407],[@b91-ol-0-0-7407]). A study in Australia and New Zealand identified an association between heterozygote carriers of the HLA-G 14-bp ins/del polymorphism and decreased risk of neuroblastoma ([@b88-ol-0-0-7407]). Another study demonstrated that the 14-bp del allele may promote human papillomavirus infection and the 14-bp del/+3142C haplotype may be involved in invasive cervical cancer (ICC) development ([@b91-ol-0-0-7407]). In addition, in Brazilian patients who smoke, the polymorphic 14-bp ins/ins genotype and 14-bp ins/+3142 G haplotypes were associated with an increased risk of high-grade squamous intraepithelial lesion (HSIL) and a higher risk of developing ICC, while the 14-bp del/del genotype and 14-bp del/+3142G haplotypes were associated with a lower risk of HSIL and cervical cancer ([@b86-ol-0-0-7407]). By contrast, no significant differences in the +14/−14 bp polymorphism frequencies were observed between patients with PTC and the healthy control group. However, the association between 14-bp polymorphisms and cancer susceptibility is discrepant in distinct ethnic populations. The presence of the HLA-G 3′UTR 14-bp sequence was observed to be associated with a reduced risk of breast cancer susceptibility in HLA-G-expressing tissues in Southeastern Iranian ([@b92-ol-0-0-7407]) and Korean patients ([@b43-ol-0-0-7407]). However, the association between HLA-G 3′UTR 14-bp sequence and breast cancer susceptibility was not observed in Brazilian patients with breast cancer ([@b93-ol-0-0-7407]). In addition, the 14-bp del/del allele was revealed to increase hepatocellular carcinoma (HCC) susceptibility in Brazilian ([@b94-ol-0-0-7407]) and Chinese ([@b87-ol-0-0-7407]) patients, but the variation was not associated with HLA-G expression and susceptibility to HCC in Korean patients ([@b95-ol-0-0-7407]).

Other polymorphisms of HLA-G have also been investigated. In Canadian populations with cervical cancer, the homozygous genotype form of the HLA-G\*01:01:02, -G\*01:06 and -G\*3′UTR 14-bp insertions were identified to be associated with a significantly increased risk for invasive cancer, compared with the wild-type heterozygous form of the HLA-G\*01:01:01 allele ([@b89-ol-0-0-7407]). Evaluating the effect of HLA-G polymorphism occurrence on nasopharyngeal carcinoma (NPC) susceptibility in Tunisian patients, researchers observed that the lle110 allele was associated with fewer lymph node metastases and an increased number of patients with higher tumor stages, and the occurrence of codon 130C deletion reduced the disease-free and overall survival rates of patients with NPC ([@b90-ol-0-0-7407]). To date, and to the best of our knowledge, HLA-G polymorphisms have not been investigated in a number of tumor types, including lung cancer, gastric cancer, colorectal cancer, melanoma, renal cell carcinoma and glioblastoma.

Therefore, HLA-G polymorphisms may be risk factors and predictive markers for several types of cancer. However, the conflicting results regarding the association between HLA-G polymorphisms and cancer susceptibility indicate that additional studies consisting of populations from different ethnicities and larger sample sizes are required.

5.. HLA-G is involved in cancer development
===========================================

Since HLA-G expression was observed in various types of cancer, the roles of HLA-G in promoting cancer progression were investigated in a number of studies ([@b17-ol-0-0-7407],[@b96-ol-0-0-7407]--[@b98-ol-0-0-7407]). Studies revealed that HLA-G and sHLA-G have multiple mechanisms of involvement in the development of malignancies ([Fig. 1](#f1-ol-0-0-7407){ref-type="fig"}).

Available evidence has demonstrated that HLA-G may be actively involved in the immune escape mechanism of tumor cells ([@b17-ol-0-0-7407]). Cancer immunoediting is an important host protection process ([@b97-ol-0-0-7407]). In this process, the immune surveillance can be divided into three essential steps, including an elimination phase, equilibrium phase and escape phase ([@b97-ol-0-0-7407]), and HLA-G is involved in each of these three phases ([@b2-ol-0-0-7407]). Several adaptive/innate immunizing molecules and cells are involved in inhibiting the elimination of tumor cells ([@b98-ol-0-0-7407]). As mentioned earlier, HLA-G could bind to its special receptors on immune effector cells, thereby blocking the proliferation and lytic function of uterine and peripheral NK cells in a physiological context ([@b4-ol-0-0-7407]). Similarly, sHLA-G released by cancer cells can bind to the receptors on NK cells and T cells, leading to the apoptosis of immune cells ([Fig. 1A](#f1-ol-0-0-7407){ref-type="fig"}). HLA-G expression in tumors such as hepatocellular carcinoma, glioma, melanoma, renal, ovarian and lung carcinoma can also protect cancer cells from NK and CTL-mediated destruction ([@b99-ol-0-0-7407],[@b100-ol-0-0-7407]) ([Fig. 1B](#f1-ol-0-0-7407){ref-type="fig"}). In addition, plasmatic sHLA-G molecules secreted by melanoma M8 cells functionally and potently inhibit NK cell cytotoxicity by weakening the lytic granules polarization toward the target cells ([@b101-ol-0-0-7407]). The formation of HLA-G and its soluble counterpart, HLA-G5, can be increased by numerous pro-inflammatory cytokines from the tumor microenvironment, including interferon (IFN)-β and IFN-γ, which enhance the protection of tumor cells from NK cell-mediated cytolysis ([@b62-ol-0-0-7407]). HLA-G can affect the equilibrium phase by allowing cancer cell persistence, resulting in the selection of tumor cells with reduced immunogenicity ([@b102-ol-0-0-7407]). Tumor development primarily occurs in the evasion phase ([@b103-ol-0-0-7407]); in this phase, tumor cells tend to express only HLA-G on the cell surface, and not molecules essential to immune recognition, leading to the rapid growth of tumor cells and the creation of a hypoxic microenvironment. Furthermore, the hypoxic microenvironment and cytokines derived by tumor-like transforming growth factor-β and IL-10 in this phase can upregulate HLA-G expression ([@b104-ol-0-0-7407]). Estrogenic G-protein-coupled estrogen receptor-1 signaling can trigger HLA-G expression by inhibiting miR148a in breast cancer cells ([@b105-ol-0-0-7407]). These mechanisms modulated by HLA-G are considered to facilitate the escape of tumor cells from the antigen-specific immune response and to create a microenvironment suitable for tumor cells ([@b98-ol-0-0-7407]).

Notably, HLA-G can be transferred from one HLA-G-expressing cell to another, a phenomenon defined as trogocytosis ([@b106-ol-0-0-7407]) ([Fig. 1C](#f1-ol-0-0-7407){ref-type="fig"}). In this manner, cancer cells transfer HLA-G-containing membrane patches to activated NK cells ([@b106-ol-0-0-7407]). NK cells receiving the HLA-G temporarily behave as regulatory suppressor cells, and acquire the ability to inhibit immune responses such as prohibiting the proliferation of immune cells and inhibiting the cytotoxic effector of neighboring NK cells ([@b106-ol-0-0-7407],[@b107-ol-0-0-7407]). T cells and DCs may also possess regulatory properties subsequent to acquiring HLA-G antigens from malignant plasma cells, providing another novel mechanism for escaping effective immune surveillance ([@b108-ol-0-0-7407]). Similarly, the HLA-G-negative tumor cells in the vicinity of HLA-G-positive cells can be protected in this way ([@b1-ol-0-0-7407]). Therefore, this phenomenon may be an important mechanism underlying immune inhibition in physical conditions as well as in pathological conditions.

During tumor development, immune cells are able to infiltrate tumors and participate in tumor formation and progression ([@b22-ol-0-0-7407],[@b98-ol-0-0-7407]). T~regs~ are one type of tumor-infiltrating lymphocyte, which serve an important role in immunologic escape of tumor cells. High tumor-infiltrating T~regs~ are associated with the poor prognosis of human malignant tumors ([@b98-ol-0-0-7407]). T~regs~ can be induced by HLA-G not only under physiological conditions but also pathological conditions ([@b22-ol-0-0-7407]). Several studies have elucidated the association between HLA-G and T~regs~ in malignant diseases ([@b38-ol-0-0-7407],[@b60-ol-0-0-7407],[@b61-ol-0-0-7407]). It has been observed that the proportion of CD4^+^CD25^+^FoxP3^+^ T~regs~ was markedly increased in the plasma of breast cancer patients when compared with that in the plasma of healthy controls, and the increase was strongly associated with sHLA-G levels ([@b38-ol-0-0-7407]). In gastric cancer, a significant positive association between HLA-G expression and the presence of tumor-infiltrating T~regs~ was observed in tumor tissues ([@b60-ol-0-0-7407]). When gastric cancer cells were co-cultured with human peripheral blood mononuclear cells *in vitro*, HLA-G overexpression in gastric cancer cells significantly enhanced the number of T~regs~ ([@b60-ol-0-0-7407]). In addition, a negative correlation between HLA-G expression and the number of CD8^+^ T lymphocytes was observed in gastric tumor tissues using immunohistochemistry ([@b61-ol-0-0-7407]). This may be attributed to CD8^+^ T lymphocyte differentiation into T~regs~, induced by HLA-G ([Fig. 1D](#f1-ol-0-0-7407){ref-type="fig"}). Taken together, these results indicate that HLA-G may be associated with tumor progression and may be involved in tumor evasion by inducing the production of T~regs~.

Another mechanism by which sHLA-G promotes cancer development is to inhibit the chemokine receptors expressed on NK/T/B cells ([Fig. 1E](#f1-ol-0-0-7407){ref-type="fig"}), which can regulate the migration and recruitment of these cells by binding with chemotactic cytokines ([@b109-ol-0-0-7407]). Several studies have demonstrated that sHLA-G reduces the expression of CCR2/CXCR3/CXCR5 on T cells, downregulates CCR2/CXCR3/CX3CR1/CXCR5 expression on NK cells and inhibits CXCR4/CXCR5 expression on B cells by interacting with ILT2 ([@b109-ol-0-0-7407]--[@b111-ol-0-0-7407]). Following the loss of chemotaxic ability, NK/T/B cells cannot migrate to pathological tissues and consequently cannot regulate a series of immunological responses ([@b109-ol-0-0-7407]).

Furthermore, a previous study ([@b96-ol-0-0-7407]) determined that HLA-G may be involved in the invasion and metastasis stages of tumor progression ([Fig. 1F](#f1-ol-0-0-7407){ref-type="fig"}). In ovarian carcinoma, HLA-G expression is closely associated with matrix metalloproteinase-15 (MMP-15) expression ([@b100-ol-0-0-7407]). Knockdown of MMP-15 expression significantly decreases the migration potential and tumor metastasis of HO-8910 ovarian serous cystadenocarcinoma cells ([@b100-ol-0-0-7407]). In JEG-3 gestational choriocarcinoma cells, downregulating HLA-G expression notably suppressed the activation of STAT3 and the invasion capacity of cancer cells ([@b112-ol-0-0-7407]). These data indicate that HLA-G may regulate the malignant biological behavior of cancer cells by affecting STAT3 activation and MMP-15 expression.

In addition, *in vivo* evidence of the immunosuppression function of HLA-G in tumors was provided by a number of studies. HLA-G may interact with the murine-paired immunoglobulin-like receptor-B, ortholog of human ILT receptors, enabling the role to be investigated *in vivo* ([@b113-ol-0-0-7407]). Agaugué *et al* ([@b114-ol-0-0-7407]) first established a HLA-G^+^ xenotumor mouse model by subcutaneously injecting M8-HLA-G1 tumor cells into immunocompetent mice. This demonstrated that HLA-G serves a crucial role in immune evasion and promotes tumor expansion *in vivo* by depleting peripheral T cells and increasing blood myeloid-derived CD11b(+) Gr1(+) PIR-B(+) suppressor cells ([@b114-ol-0-0-7407]). In another study, researchers injected syngeneic hβ2m^+^ HLA-G5^+^ tumor cells (tumor cells co-expressing HLA-G5 and human β2-microglubulin) or hβ2m^+^ HLA-G5^−^ tumor cells into immunocompetent mice ([@b115-ol-0-0-7407]). The results indicated that secreted HLA-G5 protected hβ2m^+^ HLA-G5^+^ tumor cells against immune rejection elicited by hβ2 m, thereby permitting the immunogenic tumors to grow in a similar manner to poorly immunogenic tumors ([@b115-ol-0-0-7407]). These data highlight the crucial role of HLA-G in tumor immune surveillance and malignant disease progression.

6.. Role of HLA-G in the diagnosis of cancer
============================================

As aforementioned, HLA-G expression levels in tumor tissue samples and high levels of sHLA-G in plasma samples, all obtained from patients with various types of cancer, have previously been detected, and high expression was determined to be significantly associated with high histological grade, lymph node metastasis, advanced clinical stage and a poor prognosis ([@b96-ol-0-0-7407]). Therefore, the application of HLA-G as a diagnostic and prognostic biomarker of cancer has been proposed.

Studies have demonstrated that HLA-G expression was higher in malignant lesions compared with that in benign hyperplasias ([@b73-ol-0-0-7407],[@b75-ol-0-0-7407]). In thyroid tissues, the percentage of cell staining for HLA-G antigen in PTC, follicular thyroid carcinomas and follicular adenomas (FA) was significantly higher than in colloid goiter and histologically normal thyroid glands ([@b75-ol-0-0-7407]). In cervical cancer lesions, HLA-G expression was increased in patients with invasive cervical cancer compared with that in patients with CIN III, and HLA-G expression was more frequently observed in cancer lesions from patients with a higher FIGO stage of cancer ([@b73-ol-0-0-7407]). In liver tissues, HLA-G expression was identified in the primary sites of HCC, but not detected in benign lesions represented by liver cirrhosis (LC) ([@b52-ol-0-0-7407]). ELISA assay also showed that the plasma sHLA-G level in patients with HCC was higher than in LC ([@b52-ol-0-0-7407]). These results indicated that HLA-G and sHLA-G may be involved in tumorigenesis and tumor development, which provides the basis for their purpose as indicators of early diagnosis.

HLA-G expression may also be a prognostic predictor of carcinoma following curative resection ([@b50-ol-0-0-7407]). For instance, high expression levels of HLA-G in hepatocellular carcinoma are independently associated with the shortening of overall survival times and an increase in tumor recurrence ([@b50-ol-0-0-7407]). In addition, patients with high HLA-G levels and a high T~regs~:CD8^+^ ratio exhibited ≥3 times increased risk of tumor relapse and mortality, compared with those without ([@b50-ol-0-0-7407]). Therefore, the combination of HLA-G expression and the T~regs~:CD8^+^ ratio served as an improved prognosticator ([@b50-ol-0-0-7407]). In colorectal cancer, patients with HLA-G expression in tissue have a significantly shorter survival time compared with those patients with HLA-G negative, indicating that HLA-G may be an independent prognostic factor for colorectal cancer ([@b55-ol-0-0-7407]).

In addition, HLA-G expression in tissues and sHLA-G concentrations in body fluids were useful for the prediction and diagnosis of cancer patients with various subtypes ([@b44-ol-0-0-7407],[@b116-ol-0-0-7407]). When sHLA-G plasma level was detected in 120 patients with breast cancer, Provatopoulou *et al* ([@b44-ol-0-0-7407]) found that sHLA-G levels were closely associated with histological type: sHLA-G expression in patients with mixed type co-existing ductal and lobular breast lesions was significantly higher than patients with pure ductal carcinoma or pure lobular neoplasia. Furthermore, the expression of HLA-G was significantly higher in non-luminal subtypes of invasive ductal breast carcinoma compared with in luminal subtypes ([@b116-ol-0-0-7407]).

Therefore, HLA-G/sHLA-G could be used as biomarkers to diagnose cancer in the early stages, to predict the prognosis of cancer patients and be used as subsidiary indicators to distinguish various cancer subtypes of cancer. Additionally, as aforementioned, HLA-G polymorphisms may be useful in the diagnosis of cancer.

7.. HLA-G as a potential therapeutic target in cancer
=====================================================

In accordance with the important role of HLA-G in promoting tumor evolution and progression, targeting HLA-G has been deemed to be a novel innovative therapeutic strategy in cancer ([@b99-ol-0-0-7407],[@b114-ol-0-0-7407]). In human HCC cell lines, when HLA-G expression is diminished by applying the vectors containing small interfering RNA specifically targeting the HLA-G gene, a significant increase in NK cell-mediated lysis occurs, which prevents tumor progression ([@b99-ol-0-0-7407]). In xenotumor mouse models, blocking HLA-G using a specific antibody successfully inhibits the development of the tumor ([@b114-ol-0-0-7407]). Additional studies and clinical trials are required to demonstrate the value of HLA-G in targeted cancer therapy.

However, a noteworthy phenomenon to consider is that several therapeutics may induce HLA-G-negative tumors to express HLA-G, and thus contribute to cancer recurrence ([@b34-ol-0-0-7407],[@b81-ol-0-0-7407]). For example, a multicentric study has demonstrated that high expression levels of HLA-G in glioblastoma may be induced by combined 5-aza-2′-deoxycytidine and interferon-γ treatments *in vitro* ([@b81-ol-0-0-7407]). Melanoma patients undergoing INF-α immunotherapy exhibited significantly enhanced increases in the serum sHLA-G level ([@b34-ol-0-0-7407]). Furthermore, it was demonstrated that HLA-G1 expression may modulate the radiosensitivity of human tumoral cell lines: HLA-G1 expressing cells had a higher radiosensitivity in human melanoma M8 and human erythroleukemia K562 cell lines ([@b117-ol-0-0-7407]). Thus, identification of HLA-G status may be conducive to improved selection of cancer patients who could benefit from more tailored immunological therapy or neoadjuvant biological therapy.

8.. Conclusion
==============

In conclusion, HLA-G is a potent immune-inhibitory molecule in healthy individuals and in pathological organisms. Although the frequency of HLA-G/sHLA-G expression and its association with clinical parameters varies between different cancer types, and even between different studies of the same tumor type, HLA-G expression in tumors has been considered to be detrimental. However, studies with a larger number of populations from different ethnicities are required.

Considering the ectopic expression of HLA-G and its gene polymorphisms in tumors, it is promising that membrane-bound and sHLA-G could be a potential diagnostic biomarker to identify tumors and to monitor disease stage. Since HLA-G has been demonstrated to be an important molecule in tumor immune escape and cancer development, blockade of HLA-G expression or elimination of HLA-G-expressing cancer cells may be important to the efficacy of anticancer therapies. Thus far, several molecular inhibitors have demonstrated their ability to specifically target the HLA-G gene; however, additional studies involving higher animals and clinical trials involving humans are required in order for these inhibitors targeting HLA-G to be used clinically.

The present study was financially supported by the National Natural Science Foundation of China (grant no. 81372334).

![HLA-G and sHLA-G ae involved in the development of malignancies in multiple ways. (A) sHLA-G released by cancer cells binds to the receptors on NK cells and T cells, leading to the apoptosis of immune cells. (B) The interaction between HLA-G on cancer cells and its receptors on NK/CTL cells directly inhibit the function of activated immune cells. (C) During cell-cell contact, cancer cells transfer HLA-G-containing membrane patches to activated NK/DC/T cells. NK/DC/T cells that receive HLA-G temporarily behave as regulatory suppressor cells and acquire the ability to inhibit immune responses. (D) In the presence of sHLA-G, CD4^+^ and CD8^+^ T cells lose their capability to respond to antigenic stimulation and differentiate into T~regs~, which can inhibit T cell function and facilitate immunological escape. (E) sHLA-G can inhibit the chemokine receptors expressed on NK/T/B cells by interacting with ILT2 on cells. Losing the ability of chemotaxis, NK/T/B cells cannot migrate to pathological tissues and cannot regulate a series of immunological responses. (F) HLA-G may be involved in the invasiveness and metastasis of tumor progression by increasing the expression of MMPs and STAT3. HLA-G, human leukocyte antigen-G; sHLA-G, soluble HLA-G; NK, natural killer; CTL, cytotoxic T lymphocyte; DC, dendritic cell; MMP, matrix metalloproteinase; STAT3, signal transducer and activator of transcription 3l ILT2, immunoglobulin-like transcript 2; T~regs~, regulatory T cells; Ifn, interferon.](ol-15-01-0699-g00){#f1-ol-0-0-7407}

###### 

HLA-G expression in different cancer types.

  Tumor type                   Method   Total number   HLA-G^+^ number   HLA-G^+^, %   (Refs.)
  ---------------------------- -------- -------------- ----------------- ------------- ----------------------
  Melanoma                     IHC        79             22              28.0          ([@b33-ol-0-0-7407])
  Breast cancer                IHC        52             31              59.6          ([@b35-ol-0-0-7407])
                               IHC        38             22              58.0          ([@b36-ol-0-0-7407])
                               IHC        36             14              36.0          ([@b37-ol-0-0-7407])
                               IHC        58             41              70.7          ([@b38-ol-0-0-7407])
                               IHC      235            155               66.0          ([@b39-ol-0-0-7407])
                               IHC      667            400               60.0          ([@b40-ol-0-0-7407])
                               IHC        45             28              62.0          ([@b41-ol-0-0-7407])
                               IHC        45             29              64.4          ([@b42-ol-0-0-7407])
  Lung cancer                  IHC        34               9             26.0          ([@b45-ol-0-0-7407])
                               IHC      106              79              75.0          ([@b46-ol-0-0-7407])
                               IHC      101              42              41.6          ([@b47-ol-0-0-7407])
  Hepatocellular carcinoma     IHC      173              99              57.0          ([@b50-ol-0-0-7407])
                               IHC      219            110               50.2          ([@b51-ol-0-0-7407])
                               WB         36             24              66.7          ([@b52-ol-0-0-7407])
  Colorectal cancer            RT-PCR     39             34              87.0          ([@b54-ol-0-0-7407])
                               IHC      201            130               64.6          ([@b55-ol-0-0-7407])
                               IHC      251              51              20.3          ([@b56-ol-0-0-7407])
                               IHC      102              72              70.6          ([@b57-ol-0-0-7407])
  Gastric cancer               IHC      160            113               71.0          ([@b59-ol-0-0-7407])
                               IHC      179              89              49.7          ([@b60-ol-0-0-7407])
                               IHC        52             16              31.0          ([@b61-ol-0-0-7407])
  Esophageal carcinoma         IHC      121            110               90.9          ([@b62-ol-0-0-7407])
                               IHC        79             52              65.8          ([@b63-ol-0-0-7407])
                               IHC        60             40              75.0          ([@b64-ol-0-0-7407])
                               IHC        60             42              70.0          ([@b65-ol-0-0-7407])
  Nasopharyngeal carcinoma     IHC      552            437               79.2          ([@b66-ol-0-0-7407])
  Laryngeal lesions            IHC      109            /                 /             ([@b67-ol-0-0-7407])
  Bladder TCC                  IHC        75             51              68.0          ([@b68-ol-0-0-7407])
  Renal cell carcinoma         IHC        18             11              61.0          ([@b69-ol-0-0-7407])
                               IHC        38             29              76.0          ([@b70-ol-0-0-7407])
  Clear cell renal carcinoma   IHC        12               7             58.0          ([@b71-ol-0-0-7407])
                               IHC        95             47              49.5          ([@b72-ol-0-0-7407])
  Cervical lesions             IHC      129              81              62.8          ([@b73-ol-0-0-7407])
  PT                           IHC        70             30              44.3          ([@b74-ol-0-0-7407])
                               IHC        72             56              77.8          ([@b75-ol-0-0-7407])
  FTC                          IHC        19             17              90.0          ([@b75-ol-0-0-7407])
  Neuroblastoma                IHC        12               0               0.0         ([@b76-ol-0-0-7407])
                               FC           9              9             100.0         ([@b77-ol-0-0-7407])
  Glioblastoma                 IHC          5              4             80.0          ([@b78-ol-0-0-7407])
                               IHC        26             15              58.0          ([@b79-ol-0-0-7407])
                               IHC        39             25              64.0          ([@b80-ol-0-0-7407])
                               IHC      108              65              60.2          ([@b81-ol-0-0-7407])

HLA-G, human leukocyte antigen-G; IHC, immunohistochemistry; WB, western blot analysis; RT-PCR, reverse transcription-polymerase chain reaction; FC, flow cytometry; TCC, transitional cell carcinoma of the human bladder; PTC, papillary thyroid cancer; FTC, follicular thyroid cancer.

###### 

Plasma sHLA-G level detected by ELISA.

  Tumor type                   Number (α/β)^[a](#tfn2-ol-0-0-7407){ref-type="table-fn"}^   sHLA-G concentrate (α\' vs. β\')^[b](#tfn3-ol-0-0-7407){ref-type="table-fn"}^    (Refs.)
  ---------------------------- ----------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------
  Melanoma                     190/126                                                     41.95±2.15 vs. 22.92±1.51 ng/ml^[c](#tfn4-ol-0-0-7407){ref-type="table-fn"}^     ([@b34-ol-0-0-7407])
  Breast cancer                80/80                                                       117.2 vs. 10.1 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                 ([@b43-ol-0-0-7407])
                               120/40                                                      70.59 vs. 46.05 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                ([@b44-ol-0-0-7407])
                               92/70                                                       82.19 vs. 9.65 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                 ([@b38-ol-0-0-7407])
                               44/48                                                       0.78 vs. 0.43 µg/ml^[c](#tfn4-ol-0-0-7407){ref-type="table-fn"}^                 ([@b39-ol-0-0-7407])
                               45/40                                                       35 vs. 7.6 ng/m^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                     ([@b42-ol-0-0-7407])
                               120/40                                                      70.59 vs. 46.05 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                ([@b44-ol-0-0-7407])
  Lung cancer                  91/150                                                      32.0 vs. 20.4 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                  ([@b47-ol-0-0-7407])
                               137/84                                                      34 vs. 14 ng/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                     ([@b48-ol-0-0-7407])
                               43/120                                                      64 vs. 34 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                      ([@b49-ol-0-0-7407])
  Thyroid cancer               183/245                                                     42.9 vs. 8.5 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                   ([@b83-ol-0-0-7407])
  Hepatocellular carcinoma     19/86                                                       92.49 vs. 9.29 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                 ([@b51-ol-0-0-7407])
                               36/25                                                       132.6 vs. 47.0 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                 ([@b52-ol-0-0-7407])
                               80/50                                                       178.8 vs. 6.8 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                  ([@b53-ol-0-0-7407])
  Colorectal cancer            144/60                                                      124.3 vs. 25 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                   ([@b58-ol-0-0-7407])
                               37/129                                                      84 vs. 34 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                      ([@b49-ol-0-0-7407])
  Gastric cancer               58/64                                                       130 vs. 38 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                     ([@b60-ol-0-0-7407])
                               28/120                                                      73 vs. 34 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                      ([@b49-ol-0-0-7407])
  Esophageal carcinoma         41/153                                                      152.4 vs. 8.9 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                  ([@b63-ol-0-0-7407])
                               58/120                                                      77 vs. 34 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                      ([@b49-ol-0-0-7407])
                               60/28                                                       15.04 vs. 6.81 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                 ([@b65-ol-0-0-7407])
  Bladder TCC                  15/105                                                      10.75 vs. 8.69 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                 ([@b68-ol-0-0-7407])
  Clear cell renal carcinoma   16/144                                                      39.5 vs. 19.2 U/ml^[d](#tfn5-ol-0-0-7407){ref-type="table-fn"}^                  ([@b72-ol-0-0-7407])
  Neuroblastoma                53/53                                                       26.1±6.97 vs. 4.409±0.808 ng/ml^[c](#tfn4-ol-0-0-7407){ref-type="table-fn"}^     ([@b76-ol-0-0-7407])
  AML                          47/37                                                       16.23±6.17 vs. 52.8±32.7 ng/ml^[c](#tfn4-ol-0-0-7407){ref-type="table-fn"}^      ([@b82-ol-0-0-7407])
  ALL                          28/37                                                       16.23±6.17 vs. 63.4±35.8 ng ng/ml^[c](#tfn4-ol-0-0-7407){ref-type="table-fn"}^   ([@b82-ol-0-0-7407])

α represents the number of tumor patients, β represents the number of healthy controls.

α\' represents the plasma sHLA-G level of tumor patients and β\' represents the plasma sHLA-G level of healthy controls.

Quantitative variables are expressed as the mean ± standard error of the mean.

Quantitative variables are expressed as median levels. TCC, transitional cell carcinoma; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; sHLA-G, soluble iman leukocyte antigen-G.
